Jones S, Nelson-Sathi S, Wang Y, Prasad R, Rayen S, Nandel V
Sci Rep. 2019; 9(1):14690.
PMID: 31604969
PMC: 6789102.
DOI: 10.1038/s41598-019-51097-w.
Al Khatib H, Al Thani A, Gallouzi I, Yassine H
BMC Infect Dis. 2019; 19(1):314.
PMID: 30971204
PMC: 6458790.
DOI: 10.1186/s12879-019-3930-6.
Xie X, Lin Y, Pang M, Zhao Y, Kalhoro D, Lu C
Vet Res. 2015; 46:33.
PMID: 25888728
PMC: 4364502.
DOI: 10.1186/s13567-015-0146-7.
Hooper K, Crowe Jr J, Bloom J
J Virol. 2015; 89(7):3737-45.
PMID: 25609803
PMC: 4403400.
DOI: 10.1128/JVI.00012-15.
Hufton S, Risley P, Ball C, Major D, Engelhardt O, Poole S
PLoS One. 2014; 9(8):e103294.
PMID: 25084445
PMC: 4118869.
DOI: 10.1371/journal.pone.0103294.
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.
DiLillo D, Tan G, Palese P, Ravetch J
Nat Med. 2014; 20(2):143-51.
PMID: 24412922
PMC: 3966466.
DOI: 10.1038/nm.3443.
Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model.
Guarnaccia T, Carolan L, Maurer-Stroh S, Lee R, Job E, Reading P
PLoS Pathog. 2013; 9(5):e1003354.
PMID: 23671418
PMC: 3649996.
DOI: 10.1371/journal.ppat.1003354.
Antibody pressure by a human monoclonal antibody targeting the 2009 pandemic H1N1 virus hemagglutinin drives the emergence of a virus with increased virulence in mice.
ODonnell C, Vogel L, Wright A, Das S, Wrammert J, Li G
mBio. 2012; 3(3).
PMID: 22647789
PMC: 3372962.
DOI: 10.1128/mBio.00120-12.
Therapeutics against influenza.
Govorkova E, McCullers J
Curr Top Microbiol Immunol. 2012; 370:273-300.
PMID: 22246228
PMC: 7121838.
DOI: 10.1007/82_2011_198.
Identification of amino acids in highly pathogenic avian influenza H5N1 virus hemagglutinin that determine avian influenza species specificity.
Li Z, Liu Z, Ma C, Zhang L, Su Y, Gao G
Arch Virol. 2011; 156(10):1803-12.
PMID: 21744000
PMC: 7086585.
DOI: 10.1007/s00705-011-1056-2.
Preventing and treating secondary bacterial infections with antiviral agents.
McCullers J
Antivir Ther. 2011; 16(2):123-35.
PMID: 21447860
PMC: 4907367.
DOI: 10.3851/IMP1730.
Evaluation of diagnostic applications of monoclonal antibodies against avian influenza H7 viruses.
Yang M, Clavijo A, Graham J, Pasick J, Neufeld J, Berhane Y
Clin Vaccine Immunol. 2010; 17(9):1398-406.
PMID: 20660135
PMC: 2944461.
DOI: 10.1128/CVI.00023-10.
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Du L, Zhao G, Zhang X, Liu Z, Yu H, Zheng B
Biochem Biophys Res Commun. 2010; 397(3):580-5.
PMID: 20617558
PMC: 7092825.
DOI: 10.1016/j.bbrc.2010.05.161.
Seasonal influenza vaccine and protection against pandemic (H1N1) 2009-associated illness among US military personnel.
Johns M, Eick A, Blazes D, Lee S, Perdue C, Lipnick R
PLoS One. 2010; 5(5):e10722.
PMID: 20502705
PMC: 2873284.
DOI: 10.1371/journal.pone.0010722.
Evasion of innate and adaptive immune responses by influenza A virus.
Schmolke M, Garcia-Sastre A
Cell Microbiol. 2010; 12(7):873-80.
PMID: 20482552
PMC: 2897956.
DOI: 10.1111/j.1462-5822.2010.01475.x.
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.
Wang T, Tan G, Hai R, Pica N, Petersen E, Moran T
PLoS Pathog. 2010; 6(2):e1000796.
PMID: 20195520
PMC: 2829068.
DOI: 10.1371/journal.ppat.1000796.
Monoclonal antibody-based therapies for microbial diseases.
Saylor C, Dadachova E, Casadevall A
Vaccine. 2009; 27 Suppl 6:G38-46.
PMID: 20006139
PMC: 2810317.
DOI: 10.1016/j.vaccine.2009.09.105.
HIV-1 and influenza antibodies: seeing antigens in new ways.
Kwong P, Wilson I
Nat Immunol. 2009; 10(6):573-8.
PMID: 19448659
PMC: 2796958.
DOI: 10.1038/ni.1746.
